BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 72,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the sale, the chief executive officer directly owned 108,209 shares of the company’s stock, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.

BioNTech Trading Down 1.9%

Shares of BNTX stock traded down $1.81 during trading hours on Tuesday, hitting $95.83. The company had a trading volume of 882,705 shares, compared to its average volume of 1,088,476. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market capitalization of $24.23 billion, a PE ratio of -12.24 and a beta of 1.25. The company’s fifty day moving average is $98.94 and its 200 day moving average is $95.06. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the business posted ($1.60) EPS. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. Research analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Hsbc Holdings PLC purchased a new position in shares of BioNTech in the 4th quarter valued at $4,969,000. Bank of America Corp DE boosted its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares in the last quarter. Amundi grew its holdings in shares of BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after purchasing an additional 25,506 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of BioNTech during the second quarter worth about $2,520,000. Finally, Flossbach Von Storch SE acquired a new stake in shares of BioNTech during the second quarter worth about $207,142,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Canaccord Genuity Group dropped their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday. Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup reduced their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Finally, UBS Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.